Prevention

Latest News


Latest Videos


Shorts

Brian C. Castrucci, DrPH, president and CEO of the de Beaumont Foundation
0:43
Why Correlation Isn't Causation: The Shark Attack Myth
2 days ago
Brian C. Castrucci, DrPH, president and CEO of the de Beaumont Foundation
Why Public Health Is the Foundation of America
6 days ago
Brian C. Castrucci, DrPH, president and CEO of the de Beaumont Foundation
0:45
Why Disagreement Is the Engine of Science
10 days ago
Brian C. Castrucci, DrPH, president and CEO of the de Beaumont Foundation
0:46
The Difference Between a Doctor and Public Health
13 days ago
Brian C. Castrucci, DrPH, president and CEO of the de Beaumont Foundation
0:54
Why Public Health Official Fail the "First Date" Test
15 days ago
Endale Tilahun, MD, MPH, chief of party in Malawi for Project HOPE Namibia
0:56
How We Eradicated Cholera in Weeks
24 days ago
Endale Tilahun, MD, MPH, chief of party in Malawi for Project HOPE Namibia
0:56
Why Healthcare Gains Are Fragile
a month ago
Endale Tilahun, MD, MPH, chief of party in Malawi for Project HOPE Namibia
0:35
The Funding Model Transition Is Real
a month ago
Endale Tilahun, MD, MPH, chief of party in Malawi for Project HOPE Namibia If
0:54
A Message to World's Philanthropists
a month ago
Endale Tilahun, MD, MPH, chief of party in Malawi for Project HOPE Namibia
0:46
A Powerful Message to Global Philanthropists on Health Equity
a month ago


More News

Randalyn Harreld, CRCST, CIS, CER, CHL, CSPDT, CASSPT, CLS, AAS, FHSPA, clinical education manager for Steelco Belimed

Sterile processing professionals face constant interruptions, cognitive overload, increasingly complex devices, and hundreds of IFUs. Randalyn Harreld, CRCST, FHSPA, explains why health care organizations must address the human factors behind SPD performance rather than expecting frontline professionals to simply absorb ever-increasing complexity.

HIV virus  (Adobe Stock 3483234 by Yang MingQi)

Long-acting HIV therapies promise greater convenience, but fewer doses alone may not solve adherence or access challenges. Lloyd Bibby and Pooja Goyal, MS(Pharm), discuss patient choice, weekly oral and injectable therapies, health system capacity, equitable access, and the real-world measures that will define success.

A nurse and an EVS professional walk down a hospital hallway.  (Image credit: Brenna Doran with AI)

During National EVS Week, appreciation matters, but partnership matters more. Environmental services professionals bring infection prevention expertise and a unique understanding of the health care environment that can help identify barriers, improve cleaning and disinfection practices, and ultimately protect patients.

The authors discuss CBIC’s new education rules.  (Top left: Brenna Doran, PhD, MA, ACC, CIC, AL-CIP  Top right: Carole W. Kamangu, MPH, RN, CIC  Bottom: Deborah Ellis, PhD, MPH, AL-CIP, CPHQ, FACHE.)  (Image credit to Doran.)

CBIC and APIC say updated IPU requirements are intended to protect infection prevention education from commercial influence. But differing guidance, questions about industry support, and concerns about educational access leave IPs asking for a clearer, more consistent road map.

Health care workers from the US speaking with other health care workers in DRC.  (Image credit: author with AI)

Is the Ebola outbreak in the DRC getting better? The answer depends on which numbers you examine. Several important indicators are moving in the right direction, including slower case growth and a declining Rₜ. But major gaps remain in contact tracing, testing, community deaths, safe burial coverage, and treatment capacity in some of the hardest-hit areas. ICT takes a deeper look at the latest outbreak data and why the numbers suggest cautious optimism, not victory.

A laboratory setting that showcases extensive peptide research, featuring colorful models and advanced lab equipment  (Adobe Stock 1575751286 By H_Ko)

Bacteria have learned to evade many of our antibiotics. But what about defenses shaped by millions of years of evolution? An experimental peptide derived from the human immune protein CXCL10 targets resistant pathogens by exploiting a distinct bacterial vulnerability. The research is early, but the strategy could have implications far beyond a single drug candidate.

Measles outbreak and vaccination  (Adobe Stock 1971993240 by Ming)

The US effectively eliminated measles once. Now cases are climbing again, infants remain vulnerable, people have died, and vaccine misinformation is undermining one of public health's greatest achievements. The price of forgetting what vaccines prevent can be measured in lives.

Waiting-room roulette: where the patient isn’t the only one hanging around. How 3 bat sightings can grow into a 128-patient, nine-day exposure investigation. Here’s how to be ready before one finds your facility.  (Image by Brenna Doran with AI)

There’s a bat in the hospital. Now what? Before anyone swats it, grabs it, or throws it away, infection prevention needs staff to understand one thing: That bat may be critical evidence in determining whether patients and employees need rabies PEP. One bat. One bad decision. A potentially enormous exposure investigation.

Sadé L. Rolon, MBA, CMIP, CHESP, T-CHEST, T-CSCT, the regional director of operations for Sodexo’s Healthcare Division,  Julie Mangino, MD, infectious disease specialist at The Ohio State University Medical Center, Columbus, OH,  James “JJ” Odom, MBA, CHESP, CMIP, T-CHEST, the university director of buildings & grounds at UConn Health, Farmington, Connecticut,  Christopher Dugard, MS, director for the Division of Infection Control Devices in the Office of Surgical and Infection Control Devices, FDA/Center for Devices and Radiological Health.  and Elizabeth “Liz” Claverie, MS, (retired CAPT, 0-6) vice president, regulatory strategic liaison for Steris.  (Image credit: Author)

During an expert panel at Exchange26 on whole-room microbial reduction technologies, regulatory and health care leaders discussed the distinction between FDA and EPA oversight, what constitutes a medical device claim, the risks surrounding unauthorized or off-label claims, and why IP and EVS professionals should verify a device's regulatory status rather than relying solely on vendor presentations.